Clinical adverse events following COVID-19 vaccination: a scoping review of observational studies

Carlos Andres Chango Rodríguez; Jorge Antonio Segovia Guerrero; Lia Camilie Chang Huang Rivadeneira; Ariana Marisol Cañar Robles; Paolo David Torres Cañarte; Génesis Nathalie Moyano Salazar; Jessica Julieta Cañarte Moreira; Francisca Alejandra Loaiza Castro; Ana Paula Molina Recalde; Verónica Maribel Alvarez Córdova

doi:10.18203/2320-6012.ijrms20254397

Authors

Carlos Andres Chango Rodríguez Department of Medicine, Armed Forces Specialties Hospital. Quito- Ecuador
Jorge Antonio Segovia Guerrero Department of Medicine, Armed Forces Specialties Hospital. Quito- Ecuador
Lia Camilie Chang Huang Rivadeneira School of Medicine, UDLA University, Quito- Ecuador
Ariana Marisol Cañar Robles School of Medicine, UDLA University, Quito- Ecuador
Paolo David Torres Cañarte School of Medicine, USFQ University, Quito- Ecuador
Génesis Nathalie Moyano Salazar School of Medicine, USFQ University, Quito- Ecuador
Jessica Julieta Cañarte Moreira Northern Oncology Center, Antofagasta -Chile
Francisca Alejandra Loaiza Castro School of Medicine, UTE University, Quito- Ecuador
Ana Paula Molina Recalde School of Medicine, USFQ University, Quito- Ecuador
Verónica Maribel Alvarez Córdova Departament: Nutricion and Dietetics Program, UTA University, Ambato- Ecuador

DOI:

https://doi.org/10.18203/2320-6012.ijrms20254397

Keywords:

COVID-19 vaccines, Adverse reactions, Adverse events, Vaccine safety, Post-vaccination effects, Pharmacovigilance, Real-world evidence

Abstract

COVID-19 vaccination has been a central strategy to reduce severe disease and death during the pandemic. Although clinical trials demonstrated favorable safety profiles, real-world monitoring remains necessary to understand adverse reactions across diverse populations. Continuous post-authorization surveillance is essential to address concerns regarding vaccine safety and hesitancy. Objective of this study was to summarize observational evidence describing adverse reactions associated with COVID-19 vaccines in routine clinical and community environments. A scoping review was conducted following a structured methodological approach, including observational studies that evaluated post-vaccination adverse reactions. Eligible designs comprised cohort, registry-based and cross-sectional studies. Main outcomes included frequency, type, onset, severity and functional impact of adverse reactions. Eleven observational studies were included. The vaccines most frequently evaluated were Pfizer-BioNTech, Oxford-AstraZeneca, Moderna and Sinopharm. The most common reactions were local symptoms at the injection site, such as pain, tenderness and swelling, followed by systemic manifestations including fever, fatigue, headache, myalgia and chills. Most reactions appeared within the first 24 to 48 hours after vaccination, were mild or moderate in intensity and resolved spontaneously without medical intervention. Serious adverse events and fatal outcomes were uncommon, although isolated cardiovascular, neurological and allergic reactions were reported. Evidence from observational studies indicates that COVID-19 vaccines have a favorable real-world safety profile. Adverse reactions are predominantly mild, temporary and non-disabling. Continued transparent communication and post-marketing surveillance are necessary to maintain public confidence and ensure equitable uptake, particularly within vulnerable and underserved populations.

Metrics

Metrics Loading ...

References

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. DOI: https://doi.org/10.1056/NEJMoa2034577

Baden LR, El-Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. DOI: https://doi.org/10.1056/NEJMoa2035389

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Lancet. 2021;397(10269):99-111. DOI: https://doi.org/10.1016/S0140-6736(21)00976-4

Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA COVID-19 vaccines. JAMA. 2021;325(21):2201-2. DOI: https://doi.org/10.1001/jama.2021.5374

Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of local and systemic reactogenicity after COVID-19 vaccination. JAMA Netw Open. 2021;4(9):e2128423. DOI: https://doi.org/10.1001/jamanetworkopen.2021.40364

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID-Symptom Study app. Lancet Infect Dis. 2021;21(7):939-49. DOI: https://doi.org/10.1016/S1473-3099(21)00224-3

Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Abu-Hammad A, Dar-Odeh N, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577. DOI: https://doi.org/10.3390/vaccines9060577

Fernández-Prada M, Rivero-Calle I, Álvarez-García FJ, Alvaredo L, Sanz-Muñoz I, Rodríguez-Tenreiro C, et al. Clinical spectrum and characteristics of adverse reactions after COVID-19 vaccination. Vaccine. 2022;40(12):1742-1751.

McMurry TL, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-world safety profile of COVID-19 vaccines: A nationwide analysis. BMJ Open. 2022;12(6):e058200.

Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 vaccination. JAMA. 2021;326(14):1390-9. DOI: https://doi.org/10.1001/jama.2021.15072

Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA COVID-19 vaccines in the US. JAMA. 2022;327(4):331-40. DOI: https://doi.org/10.1001/jama.2021.24110

Sharff KA, Dancoes DM, Longueil JL, Johnson E, Lewis P. Myopericarditis following COVID-19 vaccination. Ann Intern Med. 2022;175(4):542-550.

Yahia F, Zaidan M, Taha HF, Al-Bakheet A. Thrombotic complications reported after COVID-19 vaccination. Thromb Res. 2021;204:104-111.

Su JR, Moro PL, Cano M, Lewis P, Donegan K, Woo EJ, et al. Anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2021;39(25):3498-503.

Monin-Aldama L, Laing AG, Muñoz-Rubio CD, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Immunogenicity of COVID-19 vaccines in cancer patients. Lancet Oncol. 2021;22(6):803-15. DOI: https://doi.org/10.1016/S1470-2045(21)00213-8

Ribas A, Sengupta R, Locke T, Kyriakopoulos C, Chandler J, Nunez B, et al. COVID-19 vaccination in cancer patients: consensus recommendations. Nat Rev Clin Oncol. 2021;18(10):619-631.

Thakkar A, Gonzalez-Leyva CA, Pagliaro LC, Romero C, Richard C, Shang J, et al. Serologic response to mRNA vaccination in patients with cancer. JAMA Oncol. 2021;7(8):1133-1138.

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 vaccine in hematologic malignancies. Blood. 2021;137(23):3165-3173. DOI: https://doi.org/10.1182/blood.2021011568

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three-dose of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021;385(7):661-3. DOI: https://doi.org/10.1056/NEJMc2108861

Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Elankumaran S, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021;174(11):1572-85. DOI: https://doi.org/10.7326/M21-1757

Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Whitaker M, et al. Differential reactogenicity by age. Lancet. 2021;398(10311):303-312.

Kadali RAK, Janagama R, Peruru S, Malayala SV. Immune responses and reactogenicity in younger adults. Clin Infect Dis. 2021;73(11):e3718-e3724.

Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccine safety profiles in older adults. BMJ. 2022;376:e068665.

Gherasim C, Dobrin N, Zugun-Eloae F, Arhire LI. Neurological reactions after vaccination. Neurol Sci. 2022;43(10):5961-5970.

Choi S, Lee S, Seo JW, Kim MJ. Pericarditis following COVID-19 vaccination. Eur Heart J. 2022;43(15):1440-1447.

Kim HW, Jenista ER, Wendell DC. Cardiac inflammation after mRNA COVID-19 vaccination. Circulation. 2022;145(7):569-571.

Zheng C, Shao W, Chen X, Zhang H, Zhang P. Comparative safety outcomes between platforms. Vaccine. 2022;40(9):1284-1293.

Hossen MS, Moore JT, Siddiqi UR. Long-term post-vaccination symptoms. J Med Virol. 2023;95(1):e28376.

Brinth LS, Gad M, Olesen J. Autonomic dysfunction reported after vaccination. Clin Auton Res. 2023;33(2):171-180.

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines- new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-79. DOI: https://doi.org/10.1038/nrd.2017.243

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety evaluation in clinical vaccine recipients. J Infect Dis. 2021;224(6):1062-1071.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Reactogenicity of adenoviral platforms. Lancet. 2021;396(10267):1807-1816.

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety profile of inactivated SARS-CoV-2 vaccine. JAMA. 2021;325(1):59-69.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Adverse event monitoring in inactivated vaccine recipients. Cell Res. 2021;31(4):354-365.

Dhamanti I, Suwantika AA, Adlia A, Yamani LN, Yakub F. Adverse reactions of COVID-19 vaccines: a scoping review of observational studies. Int J Gen Med. 2023;16:609-18. DOI: https://doi.org/10.2147/IJGM.S400458